The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma

BMC Pulmonary Medicine

Volumn 14, Issue 1, 2014, Pages

  Leaker, Brian R ^a   Singh, Dave ^b   Ali, Ferhana Y ^a   Barnes, Peter J ^c   O'Connor, Brian ^a  

^a RESPIRATORY CLINICAL TRIALS LTD   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Asthma; Biomarkers; COPD; Inhaled allergen challenge; LTB4; Phosphodiesterase (PDE4); TNFa

Indexed keywords

CYTOKINE; INTERLEUKIN 6; LEUKOTRIENE B4; LIPOPOLYSACCHARIDE; MEM 1414; METHACHOLINE; NITRIC OXIDE; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ALLERGEN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLERGIC ASTHMA; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOKINE PRODUCTION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG TOLERABILITY; DYSGEUSIA; EX VIVO STUDY; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INFLAMMATORY CELL; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; TABLET FORMULATION; THORAX PAIN; TREATMENT RESPONSE; VOMITING; ADOLESCENT; BREATH ANALYSIS; CELL CULTURE; CHEMICALLY INDUCED; CLINICAL TRIAL; INHALATION TEST; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; TIME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ALLERGENS; ASTHMA; BREATH TESTS; BRONCHIAL PROVOCATION TESTS; CELLS, CULTURED; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INTERLEUKIN-6; LEUKOTRIENE B4; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; NAUSEA; NITRIC OXIDE; PHOSPHODIESTERASE 4 INHIBITORS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VOMITING; YOUNG ADULT;

EID: 84964314307     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-14-166     Document Type: Article

References (52)

1. Barnes PJ: The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008, 118:3546-3556.
2. Boswell-Smith V, Cazzola M, Page CP: Are phosphodiesterase 4 inhibitors just more theophylline? J Allergy Clin Immunol 2006, 117:1237-1243.
3. Sessler CN: Theophylline toxicity: clinical features of 116 consecutive cases. Am J Med 1990, 88:567-576.
4. Torphy TJ: Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998, 157:351-370.
5. Spina D: PDE4 inhibitors: current status. Br J Pharmacol 2008, 155:308-315.
6. Schudt C, Gantner F, Tenors H, Hatzelmann A: Therapeutic potential of selective PDE inhibitors in asthma. Pulm Pharmacol Ther 1999, 12:123-129.
7. Underwood DC, Osborn RR, Novak LB, Matthews JK, Newsholme SJ, Undem BJ, Hand JM, Torphy TJ: Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram. J Pharmacol Exp Ther 1993, 266:306-313.
8. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R: In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001, 297:280-290.
9. Harbinson PL, MacLeod D, Hawksworth R, O'Toole S, Sullivan PJ, Heath P, Kilfeather S, Page CP, Costello J, Holgate ST, Lee TH: The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergeninduced responses in asthmatic subjects. Eur Respir J 1997, 10:1008-1014.
10. van Schalkwyk E, Strydom K, Williams Z, Venter L, Leichtl S, Schmid-Wirlitsch C, Bredenbröker D, Bardin PG: Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol 2005, 116:292-298.
11. Timmer W, Leclerc V, Birraux G, Neuhäuser M, Hatzelmann A, Bethke T, Wurst W: The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo. J Clin Pharmacol 2002, 42:297-303.
12. Bousquet J, Aubier M, Sastre J, Izquierdo JL, Adler LM, Hofbauer P, Rost KD, Harnest U, Kroemer B, Albrecht A, Bredenbröker D: Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy 2006, 61:72-78.
13. Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM: Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 176:154-161.
14. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF, groups M-aM-s: Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009, 374:695-703.
15. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ, groups M-aM-s: Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009, 374:685-694.
16. Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, Schudt C, Tenor H: The preclinical pharmacology of roflumilast-a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2010, 23:235-256.
17. Singh D, Richards D, Knowles RG, Schwartz S, Woodcock A, Langley S, O'Connor BJ: Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. Am J Respir Crit Care Med 2007, 176:988-993.
18. Singh D, Petavy F, Macdonald AJ, Lazaar AL, O'Connor BJ: The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Respir Res 2010, 11:26.
19. Knowles RG, Tralau-Stewart C, Dawson J, Hart GJ, Angell AD, Solanke YE, Lucas FS, Wiseman JO, Ward P, Williamson RA: In Vitro Characterisation of GSK256066, an Exceptionally High Affinity and Selective Inhibitor of PDE4 Suitable for Topical Administration. Am J Respir Crit Care Med 2009:A4581. http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference. 2014.189.1_MeetingAbstracts.A4175
20. Singh D, Leaker BR, Boyce M, Nandeuil MA, Collarini S, Mariotti F, Santoro D, Barnes PJ: The Effect Of The Inhaled PDE4 Inhibitor CHF6001 On Allergen-Induced Inflammation In Asthmatic Subjects. Am J Respir Crit Care Med 2014, 198:A4175.
21. Palmqvist M, Bruce C, Sjöstrand M, Arvidsson P, Lötvall J: Differential effects of fluticasone and montelukast on allergen-induced asthma. Allergy 2005, 60:65-70.
22. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M: Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007, 370:1422-1431.
23. Duong M, Gauvreau G, Watson R, Obminski G, Strinich T, Evans M, Howie K, Killian K, O'Byrne PM: The effects of inhaled budesonide and formoterol in combination and alone when given directly after allergen challenge. J Allergy Clin Immunol 2007, 119:322-327.
24. Gauvreau GM, Boulet LP, Postma DS, Kawayama T, Watson RM, Duong M, Deschesnes F, De Monchy JG, O'Byrne PM: Effect of low-dose ciclesonide on allergen-induced responses in subjects with mild allergic asthma. J Allergy Clin Immunol 2005, 116:285-291.
25. Inman MD, Watson RM, Rerecich T, Gauvreau GM, Lutsky BN, Stryszak P, O'Byrne PM: Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. Am J Respir Crit Care Med 2001, 164:569-574.
26. Virchow JC, Walker C, Hafner D, Kortsik C, Werner P, Matthys H, Kroegel C: T cells and cytokines in bronchoalveolar lavage fluid after segmental allergen provocation in atopic asthma. Am J Respir Crit Care Med 1995, 151:960-968.
27. O'Byrne PM: Allergen-induced airway inflammation and its therapeutic intervention. Allergy Asthma Immunol Res 2009, 1:3-9.
28. Gauvreau GM, Boulet LP, Schmid-Wirlitsch C, Côté J, Duong M, Killian KJ, Milot J, Deschesnes F, Strinich T, Watson RM, Brendenbroker D, O'Byrne PM: Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects. Respir Res 2011, 12:140.
29. Roquet A, Dahlen B, Kumlin M, Ihre E, Anstren G, Binks S, Dahlen SE: Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med 1997, 155:1856-1863.
30. Halim TY, Steer CA, Matha L, Gold MJ, Martinez-Gonzalez I, McNagny KM, McKenzie AN, Takei F: Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation. Immunity 2014, 40:425-435.
31. Oliphant CJ, Hwang YY, Walker JA, Salimi M, Wong SH, Brewer JM, Englezakis A, Barlow JL, Hams E, Scanlon ST, Ogg GS, Fallon PG, McKenzie AN: MHCII-mediated dialog between group 2 innate lymphoid cells and CD4+ T cells potentiates type 2 immunity and promotes parasitic helminth expulsion. Immunity 2014, 41:283-295.
32. St John AL, Abraham SN: Innate immunity and its regulation by mast cells. J Immunol 2013, 190:4458-4463.
33. Qian Y, Girard V, Martin CA, Molimard M, Advenier C: Rolipram, but not siguazodan or zaprinast, inhibits the excitatory noncholinergic neurotransmission in guinea-pig bronchi. Eur Respir J 1994, 7:306-310.
34. Fernandes LB, Ellis JL, Undem BJ: Potentiation of nonadrenergic noncholinergic relaxation of human isolated bronchus by selective inhibitors of phosphodiesterase isozymes. Am J Respir Crit Care Med 1994, 150:1384-1390.
35. Barnes PJ: Overview of neural mechanisms in asthma. Pulm Pharmacol 1995, 8:151-159.
36. Kidney JC, Boulet LP, Hargreave FE, Deschesnes F, Swystun VA, O'Byrne PM, Choudry N, Morris MM, Jennings B, Andersson N, Andreasson A, Cockcroft DW: Evaluation of single-dose inhaled corticosteroid activity with an allergen challenge model. J Allergy Clin Immunol 1997, 100:65-70.
37. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR: Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005, 352:2163-2173.
38. Price D, Ryan D, Burden A, Von Ziegenweidt J, Gould S, Freeman D, Gruffydd-Jones K, Copland A, Godley C, Chisholm A, Thomas M: Using fractional exhaled nitric oxide (FeNO) to diagnose steroid-responsive disease and guide asthma management in routine care. Clin Transl Allergy 2013, 3:37.
39. Kharitonov SA, Barnes PJ: Exhaled biomarkers. Chest 2006, 130:1541-1546.
40. Montuschi P, Corradi M, Ciabattoni G, Nightingale J, Kharitonov SA, Barnes PJ: Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. Am J Respir Crit Care Med 1999, 160:216-220.
41. Majid H, Kao C: Utility of exhaled nitric oxide in the diagnosis and management of asthma. Curr Opin Pulm Med 2010, 16:42-47.
42. Kanniess F, Richter K, Böhme S, Jörres RA, Magnussen H: Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma. Eur Respir J 2002, 20:853-858.
43. Gale DD, Landells LJ, Spina D, Miller AJ, Smith K, Nichols T, Rotshteyn Y, Tonelli A, Lacouture P, Burch RM, Page CP, O'Connor BJ: Pharmacokinetic and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE)4 inhibitor V11294A in healthy volunteers. Br J Clin Pharmacol 2002, 54:478-484.
44. Jin SL, Conti M: Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci U S A 2002, 99:7628-7633.
45. Jin SL, Goya S, Nakae S, Wang D, Bruss M, Hou C, Umetsu D, Conti M: Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol 2010, 126:1252-1259. e1212.
46. Jin SL, Lan L, Zoudilova M, Conti M: Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J Immunol 2005, 175:1523-1531.
47. Schudt C, Tenor H, Hatzelmann A: PDE isoenzymes as targets for antiasthma drugs. Eur Respir J 1995, 8:1179-1183.
48. Sanz MJ, Cortijo J, Morcillo EJ: PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression. Pharmacol Ther 2005, 106:269-297.
49. Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, Bartlett JB, Loveland MA, Gilhar A, Cheung YF, Baillie GS, Houslay MD, Man HW, Muller GW, Stirling DI: Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010, 159:842-855.
50. Hansen G, Jin S, Umetsu DT, Conti M: Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. Proc Natl Acad Sci U S A 2000, 97:6751-6756.
51. Page CP, Spina D: Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol 2012, 12:275-286.
52. Spina D, Landells LJ, Page CP: The role of phosphodiesterase enzymes in allergy and asthma. Adv Pharmacol 1998, 44:33-89.